The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma.
 
Kenneth F. Grossmann
Consulting or Advisory Role - Roche/Genentech
 
Megan Othus
No Relationships to Disclose
 
Ahmad A. Tarhini
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Morphotek; Novartis; Pfizer
 
Sapna Pradyuman Patel
No Relationships to Disclose
 
John M. Kirkwood
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck
Research Funding - Prometheus (Inst)
 
James Moon
No Relationships to Disclose
 
Vernon K. Sondak
Honoraria - Merck/Schering Plough
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck/Schering Plough; Novartis; Provectus
 
Antoni Ribas
Stock and Other Ownership Interests - Compugen; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Merck Sharp & Dohme (Inst)